Log In
BCIQ
Print this Print this
 

tianeptine (REV-001)

  Manage Alerts
Collapse Summary General Information
Company Revive Therapeutics Ltd.
DescriptionTricyclic compound with a dibenzothiazepine structure
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard Indication Neurology (unspecified)
Indication DetailsTreat opioid-induced respiratory depression
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$4.7M

$4.7M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/13/2014

$4.7M

$4.7M

0

Get a free BioCentury trial today